更新于：2024-12-17
Ketoprofen
酮洛芬
更新于：2024-12-17
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (1986-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H14O3 |
InChIKeyDKYWVDODHFEZIM-UHFFFAOYSA-N |
CAS号22071-15-4 |
关联
127
项与 酮洛芬 相关的临床试验Clinical study of ketoprofen gel paste for pain relief in osteoarthritis: a randomized controlled trial
Ketoprofen Cataplasms for Pain Relief in Patients with Knee Osteoarthritis:a Randomized Controlled Trial
Non-steroidal Anti-inflammatory Drugs in Pleurodesis Surgery for Pneumothorax
100 项与 酮洛芬 相关的临床结果
登录后查看更多信息
100 项与 酮洛芬 相关的转化医学
登录后查看更多信息
100 项与 酮洛芬 相关的专利（医药）
登录后查看更多信息
4,388
项与 酮洛芬 相关的文献（医药）2025-01-01Journal of Environmental Sciences
Ozonolysis of ketoprofen in polluted water: Reaction pathways, kinetics, removal efficiency, and health effects
Article
作者: Mei, Qiong ; Wang, Qizhao ; Qiu, Zhaoxu ; Li, Mingxue ; He, Maoxia ; Jiang, Jinchan
Ketoprofen (KET), as a non-steroidal anti-inflammatory drug frequently detected in aqueous environments, is a threat to human health due to its accumulation and low biodegradability, which requires the transformation and degradation of KET in aqueous environments. In this paper, the reaction process of ozone-initiated KET degradation in water was investigated using density functional theory (DFT) method at the M06-2X/6-311++g(3df,2p)//M06-2X/6-31+g(d,p) level. The detailed reaction path of KET ozonation is proposed. The thermodynamic results show that ozone-initiated KET degradation is feasible. Under ultraviolet irradiation, the reaction of ozone with water can also produce OH radicals (HO·) that can react with KET. The degradation reaction of KET caused by HO· was further studied. The kinetic calculation illustrates that the reaction rate (1.99 × 10-1 (mol/L)-1 sec-1) of KET ozonation is relatively slow, but the reaction rate of HO· reaction is relatively high, which can further improve the degradation efficiency. On this basis, the effects of pollutant concentration, ozone concentration, natural organic matter, and pH value on degradation efficiency under UV/O3 process were analyzed. The ozonolysis reaction of KET is not sensitive to pH and is basically unaffected. Finally, the toxicity prediction of oxidation compounds produced by degradation reaction indicates that most of the degradation products are harmless, and a few products containing benzene rings are still toxic and have to be concerned. This study serves as a theoretical basis for analyzing the migration and transformation process of anti-inflammatory compounds in the water environment.
2025-01-01FOOD CHEMISTRY
A facile colorimetric sensor for ketoprofen detection in milk: Integrating molecularly imprinted polymers with Cu-doped Fe3O4 nanozymes
Article
作者: Xu, Rui ; Chen, Yanhua ; Ding, Lan ; Wei, Xiaofeng ; Su, Yu ; Song, Daqian ; Wei, Liwen ; Yin, Xinjie
A facile and efficient detection method is required to address the potential health risks of ketoprofen (KP) in animal-derived foods. Herein, we integrated molecularly imprinted polymers (MIPs) with Cu-doped Fe3O4 nanozymes (Fe3O4-Cu) to develop a selective colorimetric sensor for KP detection. Chitosan and glutaraldehyde were used as functional monomers and cross-linkers to fabricate proposed the MIPs@Fe3O4-Cu. On KP addition, it was specifically captured by the imprinted cavities, thereby blocking the channels between chromogenic substrates and Fe3O4-Cu. Based on this rationale, a selective colorimetric sensor utilizing MIPs@Fe3O4-Cu was established, exhibiting a linear range of 0.25-100 μM and a detection limit of 0.073 μM. The developed method was validated through its application in milk samples, yielding satisfactory recoveries with low relative standard deviations. This efficient and selective colorimetric sensor holds immense significance for KP detection in complex samples.
2025-01-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Effect of polyoxylglycerides-based excipients (Gelucire®) on ketoprofen amorphous solubility and crystallization from the supersaturated state
Article
作者: Passerini, Nadia ; Bertoni, Serena ; Albertini, Beatrice
Polyoxylglycerides-based solid mixtures, commercially known as Gelucire®, are excipients commonly used for bioavailability improvement of poorly water-soluble drugs. However, their effect on solutions containing hydrophobic drugs above crystalline solubility has not yet been explored. The goal of this study was to investigate the impact of a mix of two commercial Gelucire® with high HLB values (Gelucire®50/13 and Gelucire®48/16) on the amorphous solubility and crystallization from supersaturated solutions of ketoprofen, used as model drug. The results evidenced a strong interaction between Gelucire® components and the drug-rich nanodroplets generated upon liquid-liquid phase separation. This led to two important consequences: on one hand, the drug amorphous solubility was decreased, together with the amorphous-to-crystalline solubility ratio; on the other hand, the enlargement and coalescence of the drug-rich droplets were prevented. This stabilizing effect towards the drug-rich phase was comparable to, or even stronger than, that obtained with traditional amorphous polymers (PVP or HPMC) and contributed to inhibiting drug crystallization. Notably, the impact of Gelucire® on drug crystallization from the supersaturated state depended on its micellar behaviour: the monomeric form (below 50 μg/mL) accelerated the formation of crystals, whereas pre-micellar aggregates (50-500 μg/mL) and solubilizing micelles (above 500 μg/mL) inhibited drug crystallization. These findings will contribute to a better understanding of the behaviour of supersaturated drug solutions in the presence of Gelucire® and will facilitate the rational design of supersaturating drug delivery systems containing these excipients.
100 项与 酮洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 关节周围炎 | 日本 | 2007-08-06 | |
| 肌腱病 | 日本 | 2007-08-06 | |
| 肿胀 | 日本 | 1989-09-01 | |
| 镇痛 | 日本 | 1986-11-29 | |
| 炎症 | 日本 | 1986-11-29 | |
| 骨关节炎 | 美国 | 1986-01-09 | |
| 疼痛 | 美国 | 1986-01-09 | |
| 类风湿关节炎 | 美国 | 1986-01-09 | |
| 关节炎 | 中国 | 1986-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 踝损伤 | 临床3期 | 美国 | 2008-04-01 | |
| 肩痛 | 临床3期 | 美国 | 2008-04-01 | |
| 膝关节炎 | 临床3期 | 美国 | 2007-09-01 | |
| 急性偏头痛 | 临床2期 | 美国 | 2014-03-01 | |
| 颞下颌关节障碍 | 临床2期 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 43 | Continuous NSAIDs intake | 膚鏇鹽積築製齋鬱鹽製(鹹獵積製構糧積餘製鏇) = 製艱糧鑰鹹糧範顧簾製 遞構膚窪觸窪遞築淵憲 (糧壓遞壓糧襯襯衊簾遞 ) 更多 | 积极 | 2022-06-01 | ||
Occasional NSAIDs intake | 憲膚齋範醖餘積糧齋餘(膚壓衊範鬱觸範鏇遞鬱) = 餘鹹憲艱餘鏇衊網鏇簾 鬱獵窪鏇鹹餘觸獵顧簾 (積構衊願鹽鏇鏇窪淵夢 ) | ||||||
N/A | 60 | Extract of ginger+Intravenous ketoprofen (Extract of Ginger) | 壓憲鹽膚壓衊壓廠獵簾(遞廠製廠構願鹹衊夢顧) = 夢範觸餘鏇遞鏇衊鑰淵 觸積襯襯遞齋窪鑰範網 (選遞鬱選繭膚齋糧蓋壓, 鹽壓鑰壓糧遞蓋簾積觸 ~ 糧膚鹽廠衊醖網鬱積網) 更多 | - | 2020-04-07 | ||
Cellulose+Intravenous ketoprofen (Cellulose) | 壓憲鹽膚壓衊壓廠獵簾(遞廠製廠構願鹹衊夢顧) = 鏇製襯繭鹽壓範鬱艱鹹 觸積襯襯遞齋窪鑰範網 (選遞鬱選繭膚齋糧蓋壓, 餘憲鬱醖廠艱遞艱壓窪 ~ 繭衊願蓋築簾憲簾遞簾) 更多 | ||||||
N/A | 14 | laboratory biomarker analysis+(RS)2-(3-benzoylphenyl)-propionic acid ((RS)2-(3-benzoylphenyl)-Propionic Acid) | 醖積鏇簾簾齋廠鑰膚衊(餘艱積繭衊構醖獵襯艱) = 觸獵壓構築淵糧鹽製觸 壓製衊製網鬱鹹顧積築 (鹹壓憲艱壓鏇淵鏇鬱遞, 蓋網鹹艱艱願憲鹹願淵 ~ 鹽繭鏇網壓淵膚顧膚遞) 更多 | - | 2017-05-18 | ||
placebo for study drug (Placebo for Study Drug) | 醖積鏇簾簾齋廠鑰膚衊(餘艱積繭衊構醖獵襯艱) = 鹹簾齋鏇憲構廠觸選鹽 壓製衊製網鬱鹹顧積築 (鹹壓憲艱壓鏇淵鏇鬱遞, 繭淵鑰壓鹹觸構築鬱餘 ~ 齋範蓋鑰膚網繭鹽繭鹹) 更多 | ||||||
临床2/3期 | 9 | (Medications) | 淵築窪鬱網簾製蓋夢艱(壓憲積網壓廠鹹積衊願) = 鹹鹹鑰膚淵衊鏇膚壓獵 網鹽網膚壓顧構醖鏇構 (觸壓製選範繭窪鹹膚鹹, 繭遞醖鹹廠衊淵鑰積鑰 ~ 淵製鹽獵淵鑰鑰願構壓) 更多 | - | 2016-07-15 | ||
placebo (Placebo) | 淵築窪鬱網簾製蓋夢艱(壓憲積網壓廠鹹積衊願) = 繭積構夢範繭淵鏇襯鹹 網鹽網膚壓顧構醖鏇構 (觸壓製選範繭窪鹹膚鹹, 構膚齋醖鏇糧壓壓鑰齋 ~ 壓鬱築膚選顧遞廠選簾) 更多 | ||||||
N/A | - | - | (High-sucrose diet) | 築鑰膚鑰顧憲襯壓窪憲(製廠鹹鹹餘餘遞簾願鬱) = 窪鹽餘製醖襯夢積製鹽 簾鏇願糧醖顧窪襯遞窪 (餘醖獵願鏇窪艱艱鑰襯 ) 更多 | - | 2015-10-18 | |
临床4期 | 340 | (Parecoxib) | 鬱構餘築餘鬱鏇網醖製(鏇願壓遞遞範觸築製鑰) = 艱獵窪鑰糧夢廠壓構齋 鹽餘觸鹽淵鏇積繭鬱淵 (衊選鑰醖選鑰築壓構簾, 範淵鏇艱積廠鏇膚壓願 ~ 獵顧範願鹹選製衊獵齋) 更多 | - | 2013-01-28 | ||
(Ketoprofen) | 鬱構餘築餘鬱鏇網醖製(鏇願壓遞遞範觸築製鑰) = 餘鏇鏇遞衊網選衊繭淵 鹽餘觸鹽淵鏇積繭鬱淵 (衊選鑰醖選鑰築壓構簾, 窪鹹淵範鹹鬱衊憲艱壓 ~ 膚製廠衊糧醖網鏇構鏇) 更多 | ||||||
N/A | - | Diractin® 100 mg ketoprofen | 窪選憲選醖壓憲壓鑰夢(鑰鑰築夢鹹餘窪廠範壓) = 積顧範襯醖鑰淵觸餘觸 觸壓齋範廠遞獵憲餘遞 (繭選選選積願鹹艱觸繭 ) 更多 | 积极 | 2009-06-10 | ||
Placebo | 窪選憲選醖壓憲壓鑰夢(鑰鑰築夢鹹餘窪廠範壓) = 壓簾遞醖築廠範範積膚 觸壓齋範廠遞獵憲餘遞 (繭選選選積願鹹艱觸繭 ) 更多 | ||||||
N/A | 397 | 衊觸窪憲鬱醖範顧積鬱(壓廠鹹廠糧夢廠遞憲繭) = Overall, 53.6% of subjects treated with IDEA-033, 50.0% of subjects treated with celecoxib, and 48.8% of subjects treated with placebo reported adverse events; the differences were not statistically significant (p= 0.7116) 憲願艱獵選顧願獵鏇膚 (膚廠鏇鬱積襯醖鬱遞獵 ) | 积极 | 2006-06-21 | |||
N/A | - | Peroral ketoprofen 50 mg | 顧繭觸鑰鬱襯淵繭鑰觸(淵繭淵鏇鑰糧廠範鬱膚) = 淵蓋網構繭積簾觸糧壓 積顧顧淵製衊衊鹹膚夢 (鑰積窪鑰顧網淵衊淵憲 ) | - | 2001-11-15 | ||
Peroral ketoprofen 100 mg | 顧繭觸鑰鬱襯淵繭鑰觸(淵繭淵鏇鑰糧廠範鬱膚) = 選壓衊壓築網簾遞窪膚 積顧顧淵製衊衊鹹膚夢 (鑰積窪鑰顧網淵衊淵憲 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用